UNSPSC 51131710: Eptifibatide

This classification denotes an antiplatelet agent with the molecular formula C35H49N11O9S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NA8320J834, chemically known as 1,2,3-trihydroxypropanol but generally known as eptifibatide, which bears US NIH Compound Identifier 753. European Medicines Agency schedules Eptifibatide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12498MIG.

UNSPSC 51131710 Eptifibatide, a Commodity code, shows no relevant recent state and local procurement activity. The sole recent opportunity tagged under this code — Sourcewell RFP #061626 for law enforcement equipment, posted May 12, 2026 with response due June 16, 2026 — is plainly unrelated to eptifibatide, an intravenous antiplatelet medication used in acute coronary syndrome treatment. The solicitation seeks to establish a cooperative purchasing contract for law enforcement equipment such as protective gear, weapons, and tactical systems available to thousands of governmental agencies across the United States and Canada, with participation from Washington state counties including Franklin, Grant, Grays Harbor, Chelan, and Yakima. This mismatch suggests either a coding error in the sourced database or that eptifibatide procurement through state and local channels does not currently generate tagged opportunities in publicly available notice systems. No other recent opportunities under this code appear in the source material.

Business development professionals should verify whether their firm's eptifibatide products or services are genuinely positioned for state and local public-sector distribution channels — such as through state medicaid formulary contracts, public health agency purchases, or hospital system cooperative agreements — before pursuing activity under this code. If the firm does supply eptifibatide to state or local buyers, expect procurement to flow through health-care specific codes, formulary management RFPs, or pharmaceutical vendor agreements rather than through this commodity designation.